PLRX - NASDAQ
Pliant Therapeutics, Inc.
$1.18
-1.7%Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live SnapshotPliant Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Pliant Therapeutics, Inc. Balance Sheet
PLRX • NASDAQ
| Pliant Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
45.4M | 71.2M | 63.2M | 33.7M | 51.7M | 50.9M | 85.8M | 60.9M | 4.3M | |
145.5M | 284.5M | 431M | 297.5M | 148.9M | 226M | 17M | 0.0 | 0.0 | |
190.9M | 355.7M | 494.2M | 331.2M | 200.6M | 276.9M | 102.8M | 60.9M | 4.3M | |
823K | 2.3M | 3M | 3.1M | 2.5M | 9.4M | 7.4M | 500K | 0.0 | |
823K | 2.3M | 3M | 2M | 2M | 9.3M | 7.1M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 1.2M | 468K | 83K | 333K | 500K | 0.0 | |
0.0 | 4.1M | 7M | 5.8M | 6.2M | 4.5M | 1.7M | 284K | 206K | |
4.7M | 163K | 1.3M | 173K | 156K | 0.0 | 0.0 | 0.0 | 250K | |
196.4M | 362.3M | 505.5M | 340.3M | 209.4M | 290.8M | 111.9M | 61.7M | 4.7M | |
NON-CURRENT ASSETS | |||||||||
25M | 32.8M | 4.8M | 9.9M | 10.9M | 4.3M | 4.1M | 4.3M | 1.8M | |
3.8M | 1.9M | 1.9M | 394K | 838K | 451K | 3.1M | 536K | 0.0 | |
28.8M | 34.7M | 6.7M | 10.3M | 11.8M | 4.8M | 7.2M | 4.8M | 1.8M | |
225.2M | 396.9M | 512.2M | 350.6M | 221.2M | 295.5M | 119.1M | 66.5M | 6.6M | |
LIABILITIES | |||||||||
CURRENT LIABILITIES | |||||||||
480K | 6M | 4.5M | 1.6M | 3M | 2M | 1.3M | 2.6M | 1.6M | |
480K | 6M | 4.5M | 1.6M | 3M | 2M | 1.3M | 2.6M | 1.6M | |
0.0 | 26.7M | 13.6M | 12.7M | 6.8M | 4.9M | 6.9M | 2.4M | 1.6M | |
1.4M | 542K | 1.3M | 2.5M | 1.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
14.4M | 0.0 | 9M | 7.2M | 5.2M | 4.6M | 64K | 130K | 0.0 | |
16.4M | 33.2M | 28.5M | 23.9M | 16.8M | 11.6M | 8.2M | 5.1M | 3.2M | |
NON-CURRENT LIABILITIES | |||||||||
0.0 | 30.2M | 10.1M | 9.9M | 0.0 | 0.0 | 444K | 525K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 866K | 110.4M | 61.3M | 0.0 | |
27.7M | 59.7M | 10.1M | 13.4M | 5.3M | 866K | 111.3M | 62.3M | 0.0 | |
29.1M | 30M | 1.3M | 5.9M | 7.2M | 0.0 | 444K | 525K | 0.0 | |
44M | 92.9M | 38.6M | 37.3M | 22.2M | 12.5M | 119.5M | 67.4M | 3.2M | |
SHAREHOLDERS' EQUITY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 75.9M | 70.6M | 39.9M | |
6K | 6K | 6K | 5K | 3K | 3K | 1K | 1K | 1K | |
1B | 1B | 973M | 653.7M | 414.3M | 400.9M | 0.0 | 0.0 | 0.0 | |
-859.4M | -710.1M | -499.7M | -338.4M | -215.1M | -117.8M | -76.3M | -71.5M | -36.6M | |
-15K | 321K | 345K | -2M | -201K | -32K | -1K | -1.1M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1M | 0.0 | |
181.2M | 304.1M | 473.6M | 313.3M | 199.1M | 283.1M | -435K | -882K | 3.3M | |
181.2M | 304.1M | 473.6M | 313.3M | 199.1M | 283.1M | -435K | -882K | 3.3M | |
SUMMARY | |||||||||
225.2M | 396.9M | 512.2M | 350.6M | 221.2M | 295.5M | 119.1M | 66.5M | 6.5M | |
145.5M | 284.5M | 431M | 297.5M | 148.9M | 226M | 17M | 0.0 | 0.0 | |
29.1M | 60.2M | 11.4M | 15.8M | 7.2M | 0.0 | 444K | 525K | 0.0 | |
-16.3M | -11M | -51.9M | -17.9M | -44.5M | -50.9M | -85.4M | -60.4M | -4.3M | |
61,388,154 | 61,388,154 | 61,388,154 | 61,388,154 | 61,388,154 | 61,388,154 | 61,388,154 | 61,388,154 | 61,388,154 |
SEC Filings
PLRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 14, 2026 | 2026 | |
S-3 S-3 N/A | March 30, 2026 | March 30, 2026 | ||
8-K 8-K 2026 N/A | March 30, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 10, 2025 | 2025 |
Related Guides
Continue your PLRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.